Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin Alpha 1 + SoC in EGFR Wild-Type NSCLC
NCT02906150Phase 2Unknown
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Sep 2016
- Primary completion
- May 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thymosin alpha 1 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by SciClone Pharmaceuticals (Holdings) Limited. Primary endpoint: Time to progression free survival at 12 months. Status: unknown.
02
Drugs
thymosin alpha 1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02906150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906150.